Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $4.4 million.

  • BioXcel Therapeutics' Accumulated Expenses fell 5719.61% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year decrease of 5719.61%. This contributed to the annual value of $5.8 million for FY2024, which is 5362.2% down from last year.
  • Per BioXcel Therapeutics' latest filing, its Accumulated Expenses stood at $4.4 million for Q3 2025, which was down 5719.61% from $5.1 million recorded in Q2 2025.
  • Over the past 5 years, BioXcel Therapeutics' Accumulated Expenses peaked at $26.6 million during Q3 2023, and registered a low of $4.0 million during Q1 2025.
  • In the last 4 years, BioXcel Therapeutics' Accumulated Expenses had a median value of $13.4 million in 2022 and averaged $12.6 million.
  • As far as peak fluctuations go, BioXcel Therapeutics' Accumulated Expenses surged by 9076.64% in 2023, and later tumbled by 7085.19% in 2025.
  • Quarter analysis of 4 years shows BioXcel Therapeutics' Accumulated Expenses stood at $18.7 million in 2022, then plummeted by 33.45% to $12.4 million in 2023, then tumbled by 53.62% to $5.8 million in 2024, then fell by 24.28% to $4.4 million in 2025.
  • Its Accumulated Expenses stands at $4.4 million for Q3 2025, versus $5.1 million for Q2 2025 and $4.0 million for Q1 2025.